Keylika

Keylika is a healthcare company located in Walnut Creek, CA, specializing in therapeutics. As a part of the Y-Combinator S22 batch, Keylika focuses on developing metal-based drugs using a platform synthesis technology to address unmet medical needs. The company’s pioneering product is a small molecule iron drug administered through a wearable skin patch designed to treat Iron Deficiency Anemia (IDA). This innovative approach aims to eliminate the gastrointestinal side effects commonly associated with oral iron supplements and offers a safer alternative to IV iron infusions. Keylika’s proprietary transdermal iron patch, upon approval, will be the first of its kind. Targeting a significant global health issue, Keylika addresses iron deficiency that affects approximately 1.6 billion people worldwide, including over 30 million in the US alone. The company is strategically positioned in a $17 billion US market for its initial product and utilizes proven delivery technologies to ensure optimal clinical outcomes. Keylika operates primarily in the United States, America/Canada, and offers remote and partly remote working conditions.